The MNX1 antibody targets the MNX1 (Motor Neuron and Pancreas Homeobox 1) protein, a transcription factor encoded by the MNX1 gene (previously known as HLXB9). MNX1 plays a critical role in embryonic development, particularly in motor neuron specification in the spinal cord and pancreatic β-cell differentiation. Dysregulation of MNX1 is linked to congenital disorders such as sacral agenesis and permanent neonatal diabetes mellitus. In research, MNX1 antibodies are essential tools for detecting and localizing the protein in tissues or cells via techniques like immunohistochemistry (IHC), Western blotting, or immunofluorescence. These antibodies help elucidate MNX1’s expression patterns, regulatory mechanisms, and pathological roles. MNX1 has also been implicated in cancer, with studies reporting its overexpression in certain tumors, including neuroendocrine tumors and leukemia, suggesting potential oncogenic functions. Commercially available MNX1 antibodies are typically monoclonal or polyclonal, raised in hosts like rabbits or mice, and require validation for specificity and sensitivity. Their applications span developmental biology, diabetes research, and oncology, aiding in both diagnostic and mechanistic studies. However, variability in antibody performance across experimental conditions underscores the need for rigorous optimization in different assays. Overall, MNX1 antibodies remain vital for advancing understanding of developmental and disease processes associated with this transcription factor.